Elias A. Zerhouni
Elias A. Zerhouni's purchase track record
Elias A. Zerhouni has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 1/5/2024 | OPK | $514K | +51.7% | +41.6% | +18.5% |
| 5/10/2022 | OPK | $250K | -14.3% | -36.9% | -4.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
OPKO Health Shares Rise on $722M BioReference Asset Sale. OPKO Health announced it sold BioReference laboratory assets to Labcorp for $722 million, a key part of Labcorp’s up to $872 million acquisition. The transaction was reflected in a sharp increase in OPKO’s stock price. The deal highlights OPKO’s focus on divesting non‑core assets. The move follows Labcorp’s broader strategy to expand its laboratory services.
Transaction History
| DHR | ▲ Buy | Option Exercise | 3,298 | $237K | 7/15/2026 | View on chart |
| DHR | ▼ Sell | Tax Withholding | 1,181 | $237K | 7/15/2026 | View on chart |
| DHR | ▲ Buy | Grant | 680 | $0 | 5/15/2026 | View on chart |
| DHR | ▲ Buy | Option Exercise | 3,928 | $233K | 7/15/2025 | View on chart |
| DHR | ▼ Sell | Tax Withholding | 1,209 | $233K | 7/15/2025 | View on chart |
| DHR | ▲ Buy | Grant | 577 | $0 | 5/15/2025 | View on chart |
| OPK | ▲ Buy | Grant | 500,000 | $0 | 7/24/2024 | View on chart |
| DHR | ▲ Buy | Option Exercise | 3,289 | $173K | 7/15/2024 | View on chart |
| DHR | ▼ Sell | Tax Withholding | 703 | $173K | 7/15/2024 | View on chart |
| DHR | ▲ Buy | Grant | 390 | $0 | 5/15/2024 | View on chart |
| OPK | ▲ Buy | Open Market | 100,000 | $93K | 1/5/2024 | View on chart |
| OPK | ▲ Buy | Open Market | 400,000 | $376K | 1/5/2024 | View on chart |
| OPK | ▲ Buy | Open Market | 17,000 | $15K | 1/5/2024 | View on chart |
| OPK | ▲ Buy | Open Market | 33,300 | $30K | 1/5/2024 | View on chart |
| DHR | ▲ Buy | Option Exercise | 3,490 | $177K | 7/28/2023 | View on chart |
| DHR | ▼ Sell | Tax Withholding | 682 | $177K | 7/28/2023 | View on chart |
| DHR | ▲ Buy | Grant | 430 | $0 | 5/15/2023 | View on chart |
| DHR | ▲ Buy | Grant | 372 | $0 | 5/15/2022 | View on chart |
| OPK | ▲ Buy | Open Market | 89,600 | $250K | 5/10/2022 | View on chart |
| DHR | ▼ Sell | Open Market | 3,409 | $1.1M | 11/29/2021 | View on chart |
| DHR | ▼ Sell | Other | 2,908 | $913K | 11/2/2021 | View on chart |
| DHR | ▼ Sell | Other | 3,092 | $970K | 11/2/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Danaher Expands AI Integration in Scientific Research
Danaher has announced a partnership to integrate AI into scientific research workflows, a move that could enhance its diagnostic and drug discovery capabilities. With Q3 earnings approaching, investors are watching to see if this strategic shift supports the company's recovery narrative. The stock currently trades near its 52-week high, reflecting optimism about these operational improvements.
Danaher Expands AI Integration in Scientific Research. Danaher has announced a partnership to integrate AI into scientific research workflows, a move that could enhance its diagnostic and drug discovery capabilities. With Q3 earnings approaching, investors are watching to see if this strategic shift supports the company's recovery narrative. The stock currently trades near its 52-week high, reflecting optimism about these operational improvements.